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Prescription drug subsidies for 
low-income Medicare 
beneficiaries cap out-of-pocket 
costs for insulin and other drugs 
used by diabetics. 
We will employ quasi-
experimental methods to 
examine the effects of caps on
out-of-pocket costs on 
beneficiaries’ mediation 
adherence and diabetes-related 
health outcomes.
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Evaluating Prescription 
Drug Subsidies for Diabetics
Motivation
 Rising drug prices are putting increased financial 
strain on individuals with chronic diseases such 
as diabetes
 Since 2006, out-of-pocket costs for insulin have 
doubled
 Rising out-of-pocket costs for prescription drugs 
may impede medication adherence and lead to 
poor health outcomes for diabetic patients
Outcomes and Analyses
 Primary outcomes:
• Total out-of-pocket drug spending
• Medication adherence 
• Cost-related medication non-adherence
• Hospital admissions related to diabetes
 Separate analyses will be conducted for insulin 
and oral diabetes medications 
 Secondary analysis for will be conducted 
beneficiaries with co-morbid hypertension and 
hyperlipidemia
Potential Impact
 Our study will provide evidence to 
policymakers on the impact of high out-of-
pocket drug costs for low-income diabetics
 This is relevant because several states and 
insurers are considering limits on out-of-pocket 
costs for insulin products
 The results will also demonstrate whether 
reforms to the LIS could improve medication 
outcomes among individuals most sensitive to 
rising drug costs
Data and Methods
 Data from Health and Retirement Survey linked 
to Medicare claims (5 waves, 2006-2016)
 Regression discontinuity (RD) design:
• Exploits abrupt reductions in subsidies at LIS 
thresholds among those who are otherwise 
minimally different
• Mimics a “randomized trial” within the 
vicinity of LIS thresholds
• Allows us isolate the effects of differences in 
out-of-pocket drug costs at these thresholds 
with patients’ health outcomes
Project Goals
 Publication in a peer-reviewed journal and  
presentation at scientific conferences
 Catalyze collaborative research program 
between researchers in Pitt’s Schools of 
Pharmacy and Public Health
 Generate preliminary data for an R21 or R01 
grant proposal
 Support research training opportunities for one 
PhD student and an undergraduate at Pitt
Policy Background
 Medicare’s Part D Low-Income Subsidy (LIS) 
reduces drug co-pays and caps out-of-pocket 
costs for low-income beneficiaries
 The LIS has strict eligibility thresholds based on 
household income (135% and 150% of the 
Federal Poverty Level) and assets
 These thresholds generate sizable differences in 
expected out-of-pocket drug costs below vs. 
above 135% and 150% of FPL
